Bryan Johnson, the tech entrepreneur known globally for his obsessive quest to reverse aging, has revealed a surprising medical setback. In a recent announcement, the longevity guru shared that he has been diagnosed with autoimmune gastritis, a chronic and incurable condition where the immune system mistakenly attacks the lining of the stomach. Describing the experience in stark terms, Johnson noted that his stomach is essentially eating itself, highlighting a rare disorder that targets the parietal cells responsible for secreting the acid necessary for digestion.
The discovery came not through dramatic symptoms, but through meticulous data tracking. For years, Johnson struggled with low ferritin levels despite adjusting his diet and taking oral iron supplements. While he lacked typical red flags like anemia or severe fatigue, his medical team persisted with blood tests, an upper endoscopy, and biopsies to uncover the root cause. Experts say this reflects a common danger of the disease; because it often remains silent for years while slowly damaging the stomach lining’s ability to absorb vital nutrients like iron and vitamin B12, it is frequently overlooked even by patients receiving comprehensive healthcare.
Medical professionals emphasize that current standard care offers no cure for autoimmune gastritis, focusing instead on damage control. Treatment typically involves supplementing missing vitamins and regular endoscopic screenings to monitor for potential complications, including a slight increase in the risk of gastric cancer over time. Gastroenterologists explain that once the stomach lining is significantly damaged, much of that loss becomes permanent, leaving doctors to manage the consequences rather than stopping the immune attack itself.
True to his reputation for pushing scientific boundaries, Johnson isn’t content with simple maintenance. He has announced plans to launch an experimental investigation into his own immune cells and inflammatory signals to find specific pathways driving his disease. While he admitted that many of these prospective therapies are still in preclinical stages or yet to be built, he hopes to move beyond traditional symptom management toward a functional solution. His journey underscores a growing clinical interest in treating autoimmune conditions earlier in their progression before irreversible tissue loss occurs.
